Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status:
Active, not recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether the addition of ibrutinib will result in
prolongation of progression-free survival (PFS) when compared with rituximab alone in
treatment naïve subjects with follicular lymphoma.